

The Protective Effect of Omega3 Against Amikacin-Induced Nephrotoxicity in Rats

Afrah Thiab Hlail¹ Hadeel Rashid Faraj² Wafa S. Abdulredha³

¹Department of pharmacology and toxicology, Faculty of Pharmacy, University of Thi-Qar, Iraq.

²Department of chemistry, college of science, University of Thi-Qar, Iraq.

³Department of pharmacology and toxicology, Faculty of Pharmacy, University of Thi-Qar, Iraq.

Corresponding author: Afrah Thiab Hlail

Email: afrah.thiab@utq.edu.iq

ABSTRACT

Renal system is vital for total body homeostasis because the kidney plays a principle role in the excretion of metabolic waste products and in the regulation of extracellular fluid volume, electrolyte composition, and acid-base balance. Amikacin induced renal toxicity including a variety of pathophysiological effects i.e. inflammation, specific transporters inhibition, induction of oxidative stress and vascular alterations. Omega-3 fatty acids are unsaturated fatty acids that have a roles in human physiology including antioxidant and anti-inflammatory effects. This study was designed to examine the impact of co administration of omega 3 with therapeutic dose of amikacin for 14 days in rats on amikacin nephrotoxic effect. The animals utilized in this study were allocated into 3 groups (eight rats each) as negative control group, amikacin only group and omega 3 in concomitant with amikacin group. serum creatinine, serum urea, serum malondialdehyde (MDA) and serum glutathione (GSH) levels were determined. The results showed significant increase ($P < 0.05$) in serum creatinine, urea and malondialdehyde levels and significant decrease ($P < 0.05$) in serum GSH level in amikacin treated group compared to the corresponding level in negative control group. Moreover, significant decrease in serum creatinine, urea, MDA levels and significant increase in GSH level in group receiving omega3 with amikacin in comparison with amikacin treated group. this study demonstrated that co-administration of omega 3 with amikacin for 14 days significantly alleviate the injurious effects of the intended antibiotic on rats' kidneys.

Keywords: Amikacin, Oxidative stress, Malondialdehyde, Glutathione, Creatinine, Urea, Renal system and Omega 3

Correspondence:

Afrah Thiab Hlail

¹Department of pharmacology and toxicology, Faculty of Pharmacy, University of Thi-Qar, Iraq.

Email: afrah.thiab@utq.edu.iq

INTRODUCTION

Kidney is vital organ for body homeostasis because the kidney plays a significant role in the excretion of metabolic wastes and in extracellular fluid volume, electrolyte composition, and acid-base balance regulation. In addition, renin and erythropoietin are synthesized and released in the kidney, it also plays vital role in metabolizing vitamin D3 to the active 1, 25-dihydroxy vitamin D3 form^(1,2). Intrinsic reactivity of the chemicals with cellular macromolecules can initiate toxicity, may require bioactivation either renal or extrarenal to reactive intermediate, or may indirectly initiate injury by generation of reactive species and free radicals and ultimately inducing oxidative stress⁽³⁾. Renal cortex has high cytochrome P450 and glutathione-S-transferase activities, while renal medulla has high prostaglandin synthetase activity, which can catalyze co-oxidation of xenobiotics⁽⁴⁾. Metabolism of renal xenobiotics can result in the electrophiles or free radicals production that may covalently bind to macromolecules or causing lipid peroxidation.⁽⁵⁾

Nephrotoxicity can define as increase in baseline serum creatinine by a 50% or decrease in creatinine clearance by 50% also elevated in blood urea nitrogen. 20% of nephrotoxicity induced by drugs such as aminoglycosides, chemotherapeutic agents, angiotensin converting enzyme inhibitors, non-steroidal anti-inflammatory drugs, angiotensin receptor blockers, vancomycin, amphotericin B as well as chemicals (heavy metals like cadmium and cobalt) and radio contrast.⁽⁶⁾

Aminoglycosides is antibacterial agents act by binding to the bacterial 30S ribosomal subunit, inhibiting the


transferring of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA, making the bacteria unable to synthesize proteins essential to its growth⁽⁷⁾. They undergo glomerular filtration, and once concentrated in the urine in these segments occurs, they are known to bind to phospholipids, followed by internalization within the cell via megalin. Once inside the proximal tubular cell, they are concentrated within lysosomes and cause a stereotypical of the lysosomes disorganization termed myeloid bodies. The reduction in glomerular filtration rate (GFR) thought to be an indirect effect on the glomerulus.⁽⁸⁾ With aminoglycosides causing myeloid bodies accumulation within lysosomes and there by inhibition of lysosomal phospholipases with a resultant decrease in sphingomyelinase activity, or an extralysosomal mechanism, with inhibition of Na, K-ATPase and phospholipase C.⁽⁹⁾

One of another causes of aminoglycoside-induced nephrotoxicity is related to the lipid peroxidation, when high dose of aminoglycoside antibiotics had been used or for a long time, causing renal tissue injury⁽¹⁰⁾

Key subcellular target of aminoglycoside are lysosomes, are believed to promote cellular injury through rupture and lysosomal enzymes release into the cytoplasm after excessive accumulation of reabsorbed toxicant and lysosomal overload.^(11,12) Wojcikch Lesniak (2005) found that aminoglycoside exerts its adverse renal effect by inducing of oxidative stress,⁽¹³⁾ also found that aminoglycosides form complex with mitochondrial Fe²⁺ to catalyze the free radicals formation^(13,14), previous study showed that hydrogen peroxide generated by aminoglycoside in vitro by renal cortical mitochondria is

derived from superoxide anion; both of them may generate the hydroxyl radical.^(15,16) Serum creatinine and blood urea nitrogen characteristically increase 7 to 10 days after aminoglycoside therapy initiation. In more than half of the cases with nephrotoxicity, the decline in renal function occurs only after the therapy has been completed.^(17,18)

Amikacin is a broad-spectrum semi-synthetic aminoglycoside antibiotic derived from kanamycin A. It was discovered first in 1971 although amikacin has high antibacterial efficacy, rapid onset of action, low cost, has synergism with beta-lactam antibiotics and low resistance but its clinical use is limited because of nephrotoxicity and ototoxicity.^(19, 20 and 21)



Chemical structure of Amikacin⁽²²⁾

Amikacin AK induced renal toxicity involves a variety of pathophysiological effects i.e. inflammation, specific transporters inhibition, induction of oxidative stress and vascular alterations. The pathogenesis of nephrotoxicity is predicted due to the ability to interact with membrane anionic phospholipids electrostatically and to interrupt structure and function of membrane⁽¹²⁾. Administration of amikacin may also produce reactive oxygen and nitrogen species and induce apoptosis. Reactive species play a critical role in drug-induced renal dysfunction and toxicity to other organs⁽²³⁾. In addition, it has been proposed that aminoglycosides (e.g., Amikacin) form a complex with a mitochondrial Fe²⁺ to promote the formation of free radicals⁽²⁴⁾. Other studies reported that AK accumulated most blatantly in renal cortex then generate free radicals and the overproduction of free radicals lead to destroying of unsaturated fatty acids in cell membrane which, in turn lead to an increase in lipid peroxidation and rising of MDA level and decrease in endogenous glutathione (GSH) level in renal tissue⁽²⁵⁾. Mechanism of amikacin-induced renal impairment is attributed to oxidative stress and inflammation^(19, 20 and 21). Oxidative stress caused by excessive production of reactive oxygen species and it produces major interrelated disturbance of cellular metabolism, including

protein and nucleic acid structure alteration, DNA damage, induction of apoptosis, elevation in intracellular free calcium, damage to membrane ion transport and damaging of the cells by lipid peroxidation^(26,27). The antioxidants play a critical role in the defense against the deleterious effects of oxidant agents produced in the biological system. The protective antioxidant mechanisms involve both enzymatic substances (e.g. catalase, glutathione peroxidase and superoxide dismutase) and non-enzymatic substances (such as tocopherols, phenolic compounds, flavonoids, catechins, ascorbic acid, omega3 and carotenoids).⁽²⁸⁾ Omega-3 fatty acids are a group of fatty acids that involved two or more double bonds ("polyunsaturated"), one of this double bonds is located three carbon positions from the methyl terminus ("omega-3" or "n-3"). omega-3 fatty acids that are longer than 14 carbon cannot be synthesized in sufficient amounts in the body, so the body obtained its need from dietary sources (i.e., they are "essential" fatty acids). The parent omega-3 fatty acid, α -linolenic acid (ALA), is derived from vegetable seed oils (Figure 1)⁽²⁹⁾. ALA is converted to the longer chain omega-3 fatty acid eicosapentanoic acid in the endoplasmic reticulum via desaturase and elongase enzymes (EPA; Figure 1).




Figure 1. Elongation of omega-3 and omega-6 fatty acids ⁽²⁹⁾

Cyclooxygenase, lipoxygenase, or cytochrome P450 AA monooxygenase convert omega-6 fatty acid arachidonic acid (AA) to a host of bioactive eicosanoid products intracellularly, they involved prostaglandins, leukotrienes, thromboxanes, lipoxins, epoxyeicosatrienoates, and

hydroxyeicosatetraenoates. Some of these AA-derived eicosanoids induce prothrombotic, proinflammatory, or proarteriosclerotic effects, including platelet aggregation, vasoconstriction, chemotaxis, increased vascular permeability, and cytokine release. (Figure 2)^(30,31).




Figure 2. Synthesis of pro- and anti-inflammatory eicosanoids ⁽³¹⁾

By competing with AA both for incorporation into the lipid pool (in particular, cell membrane phospholipids) and therefore reducing the supply of AA, in addition to the enzymes involved in synthesis of eicosanoid, EPA shunts production toward eicosanoids with anti-inflammatory and antiarteriosclerotic effects (Figure 2)⁽³¹⁾. These involve down regulation of pro inflammatory cytokines⁽³³⁻³⁵⁾, and cell surface molecules involved in cell adhesion and activation^(30,32). The mechanism may include molecules such as resolvin E1, a newly discovered lipid byproduct of EPA that suppresses activation of NF- κ B⁽³⁶⁾. Omega-3 fatty acids have clinical benefits for such many inflammation-mediated diseases as rheumatoid arthritis, inflammatory bowel disease, and certain diseases of skin and nephropathies.⁽³⁷⁻⁴⁰⁾

Animals and Method

24 Male albino strain rats with an average weight of (150-200g) in each group there is 8 rats. Obtained from collage of sciences Thi-Qar University and maintained at my house under conditions of controlled temperature. The animals were fed commercial pellets.

Experimental protocol

Group1: Eight rats were injected intraperitoneally normal saline for fourteen days. This group served as negative control.

Group2: Eight rats were injected intrapritoneally 120mg/kg/day of amikacin ⁽¹⁹⁾ for 14 consecutive days. This group served as positive control of nephrotoxicity induced by amikacin.

Group 3: Eight rats received oral omega3 (100 mg /day) given once daily ⁽⁴¹⁾ concomitantly with intraperitoneal dose of amikacin (120 g/kg/day) for 14 days. This group utilized to find the protective effect of omega 3 against amikacin induced nephrotoxicity.

All animals were euthanized by anesthetic ether on day 15 and sacrificed.

Material and method

Preparation of serum samples

After euthanization of rats by anesthetic ether, blood was collected from the neck and put in plain tube; the clot was dispersed with glass rod and then centrifuged at 3000 (rpm) for 15 minutes. Serum was stored at -20°C until used for the determination of creatinine, urea, glutathione and malondialdehyde.

Biochemical analysis

Determination of serum creatinine

Serum creatinine concentrations were determined according to Jaff reaction⁽⁴²⁾ using ready-made kit for this purpose. The principle depends on the reaction of creatinine with picric acid under alkaline conditions to form a red-colored product that can be measured at 500nm. Using UNICO 1100 spectrophotometer. The red color intensity is directly proportional to creatinine concentration, which was expressed in mmol/L.

Determination of serum urea

Serum urea levels were determined using urease-modified Barthelot reaction by a ready-made kit for this purpose.⁽⁴³⁾ In alkaline medium, the ammonium ion reacts with the salicylate and hydrochlorites to form a green-colored indophenol (2,2 dicarboxyl indophenols), which can be measured spectrophotometrically at 580 nm using UNICO 1100 spectrophotometer. Levels of blood urea nitrogen were expressed in mmol/L.

Determination of serum glutathione (GSH) concentration

Total thiol groups contents, which can be used as indicator for reduced glutathione (GSH), was determined ⁽⁴⁴⁾ by enzyme linked immunoassay method by ELISA Reader supplied by, BDH chemical, Ltd., Poole, England.

Determination of serum malondialdehyde concentration

Malondialdehyde (MDA), the end product of lipid peroxidation, was measured as thiobarbituric acid (TBA) activity by using the colorimetric method recommended, MDA level of the plasma was measured according to a modified method of Fong *et al.* ^(45,46)

Statistical Analysis

Statistical analysis was performing using unpaired Student's t-test. P-values

less than 0.05 were considered significant for all data showed in the results of this study

Results

Groups of rats intraperitoneally administered 120mg /kg/ day of amikacin for 14 days showed significant increase in serum creatinine, blood urea, MDA and significant decrease in GSH activity ((P<0.05)) compared to negative control group as shown in table 1.

Table1. Effect of AK on serum creatinine, urea, MDA, and GSH in comparison with negative control group.

Group/ n=8	Serum creatinine (mmol/L)	Blood urea (mmol/L)	Serum MDA (μ mol/L)	Serum GSH (μ mol/L)
Negative Control	44.2 \pm 5.02	8.4 \pm 0.2	4.55 \pm 0.09	3.68 \pm 0.83
Intrapritoneal amikacin 120mg/kg/day for 14 consecutive days	57.4 * \pm 9.2	9.8 * \pm 0.6	7.16 * \pm 1.008	1.8 * \pm 0.51

- Each value represents Mean \pm standard deviation (SD).

- P * < 0.05 significant difference in comparison with the negative control group

-n: number of animals.

Coadministration of intraperitoneal amikacin with oral omega3 by gavage tube resulting in significant decrease($P<0.05$) in (S.cr.,urea,MDA) in comparison

with group treated with amikacin only and significant increase($P<0.05$) in GSH compared with amikacin only treated group as shown in table 2

Table 2. Effect of coadministration of omega3 and AK on serum (creatinine, urea, MDA and GSH) in comparison with amikacin treated group

Group/ n.=8	Serum creatinine(mmol/L)	Blood urea(mmol/L)	Serum MDA (μmol/L)	Serum GSH (μmol/L)
Intrapritoneal amikacin120mg/kg/day of for 14 consecutive days	57.4 ±9.2	9.8 ±0.6	7.16 ±1.008	1.8 ±0.51
Coadminstrationof orally omega 3(100 mg/day and intraperotonal amikacin120mg/kg/day	49.2*± 6.4	7.9*±0.7	4.3*±0.008	4.63*±0.978

-Legend as in table 1

In this study I noticed that there is significant decrease ($P<0.05$) in (Scr, B.urea and MDA) in group administered omega 3 (100 mg /day) with 120mg/ kg/ day of AK compared with negative control group that administered just intraperitoneal normal saline , also

there is significant increase($P<0.05$) in GSH in group administered omega 3 (100 mg /day) with AK 120mg/ kg/ day compared with negative control group that administered just intraperitoneal normal saline as shown in table 3.

Table 3. Effect of coadministration of omega3 and AK on serum (creatinine, urea, MDA and GSH) in comparison with negative control group.

Group/ n.=8	Serum creatinine(mmol/L)	Blood urea(mmol/L)	SerumMDA(μmol/L)	SerumGSH(μmol/L)
Negative Control	44.2 ±5.02	8.4 ±0.2	4.55 ±0.09	3.68 ±0.83
Coadminstration of orally omega 3 100 mg/ day and intraperotonal amikacin120mg/kg/day	49.2*± 6.4	7.9*±0.7	4.3*±0.008	4.63*±0.978

-Legend as in table 1.

Discussion and Conclusion

Nephrotoxicity is a principle complication of treatment with aminoglycoside antibiotics, that used for treatment of severe gram-negative bacterial infections (21). Amikacin possess serious nephrotoxic adverse effects which may result in acute renal injury; therefore, a study of their renal toxicity is important. Aminoglycosides reabsorbed and accumulated in the renal proximal tubular cells that results in renal injury. furthermore, tubuloglomerular degeneration resulting from generation of reactive species that creating state of oxidative stress (47). According to other studies, aminoglycosides generate reactive oxygen and nitrogen species that lead to decrease glomerular filtration rate and causing renal tubular necrosis (48, 49, 50 and 51). Baylis and Reneke, 1977 showed that aminoglycosides have ability to damage the function of glomerulus and then, reducing the output of the afferent glomerular arteriolar causing decreasing of glomerular filtration rate .Other literatures also showed significant elevation of serum creatinine and urea levels and decreased levels of creatinine clearance in amikacin treated group as a result of toxic effect of amikacin on renal system (50,52)

In this study it was found that elevation of the serum urea and creatinine in amikacin treated group compared with negative control group that give us indication of a decrease in the glomerular filtration rate. The waste products of protein metabolism are urea and creatinine

that need to be excreted by the renal system , therefore significant elevation in blood urea nitrogen and serum creatinine which found in this study reflect the state of physiological damage to the kidney caused by amikacin , also these parameters considered as biochemical markers of nephrotoxicity which may be caused by oxidative tissue damage and consequently inflammation of renal tissue.(53) Furthermore this study showed a significant elevation in malondialdehyde (MDA) which is the end product of lipid peroxidation and decrease glutathione levels in the serum of group administered amikacin compared with negative control group , this agree with most study that showed amikacin was concentrated in the cortex and produce large amount of reactive oxygen species that destroying the phospholipids membrane that causing increasing MDA level and exhausting of endogenous GSH ,also they found that after exposure to reactive oxygen species ,free radicals and oxidant substances , there is formation of MDA which is the well-known by products of lipid peroxidation and it may be used to evaluate oxidative stress by measurement of serum levels of thiobarbituric acid reactive substance(25,54,55,56and57) .As mentioned above, amikacin lead to lipid peroxidation by significantly elevated tissue MDA level, the lipid peroxidation induced by free oxygen radicals was involved in destroying and damaging the cell membrane which contribute for development of amikacin induced severe kidney damage

and these results are in agreement with studies done by Atef M. Al-Attar et al and K Kaynar et al (25,52)

Oxidative stress requires either increased reactive oxygen species formation or decreased antioxidant defence mechanism (58,59). A one of enzymatic metabolic antioxidant that protect cells from free radical toxins is glutathione (GSH) which is found usually in its reduced form, by action of glutathione reductase enzyme which revers it from its oxidized form (GSSG is constitutively active and inducible when there is oxidative stress)(57), for this reason GSH is an essential endogenous antioxidant and its level in the tissue is considered a critical determinant of the threshold for tissue injury and an explanation for decreased GSH after amikacin treatment to the increased consumption of GSH in non enzymatic and enzymatic detoxification of oxygen radicals with efflux of GSSG being the major factor in charge of maintenance of redox ratio(60,61) Concerning the results of this study which showed amikacin toxic effects is in harmony with similar other study in which a significant consumption of GSH in renal cells resulting to their damage due to elevation of lipid peroxidation(62). They were found that amikacin promote renal tissue damage via excessive oxidative stress and inflammation.(63,64). This burst of oxidative stress lead to reduction in GSH level in amikacin treated group as compared with the negative control group, amikacin induced nephrotoxicity is multifactorial depend on free radicals' formation and inflammatory responses. (63,65)

As amikacin-causig nephrotoxicity may be due to the oxidative stress; therefore, antioxidant agents could be able to attenuate amikacin -induced nephrotoxicity. according to this concept, this study is carried out to evaluate the protective effect of omega 3 because of its proven antioxidant activity.

This study show significant reduction in s.creatinine , urea, MDA, levels and significant increase in GSH level in group receiving omega3 concomitantly with amikacin in comparison with rats group administered amikacin 120 mg \kg \ day .

Omega 3 may prevents nephrotoxicity directly by scavenging ROS and RNS including hydroxyl radical ($\bullet\text{OH}$), singlet oxygen ($^1\text{O}_2$), hydrogen peroxide (H_2O_2), superoxide radical ($\text{O}_2^{\bullet -}$), nitric oxide (NO) and peroxynitrate anion (ONOO^-) and reduce their generation by inhibiting the activity of inducible nitric oxide synthase (iNOS) this agree with other study which state that

omega3 have anti-inflammatory and resolution-directed activities represent an indirect mechanism by which n-3 Poly Unsaturated Fatty Acids lowering endogenous ROS and changing cellular redox status (66).

Antioxidant effect of omega 3 may showed either directly by scavenging free radicals or indirectly by increasing the activity of antioxidant enzymes; superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), glutathione reductase (GRd) and the expression of endogenous antioxidant defense (glutathione). These antioxidant enzymes have a critical role in detoxifying of free radicals to less toxic species i.e., when SOD dismutates $\text{O}_2^{\bullet -}$ to H_2O_2 which in turn, decrease free radical mediated cellular damage ; CAT converts H_2O_2 to oxygen and water , GPX oxidizes GSH to glutathione disulfide GSSG then GRd reduce GSSG to GSH therefore, the antioxidant capability of omega3 involve reducing the ROS production which is in turn leading to improvement in renal function and GFR and correct the

serum creatinine and urea levels and this agreement with other study .

Omega-3 fatty acids (Omega-3 FAs) are considered as strong antioxidants and their role as anticancer agent has been extensively confirmed in most of the human malignancies (68, 69). Furthermore, the anti-inflammatory potential of Omega-3 FAs in many chronic diseases has been suggested (69). In addition, another finding indicates that Omega-3 FAs act synergistically with certain chemotherapeutic agents(18). Omega-3 FAs were found to play protective roles in the liver, cardiovascular system, and kidney and they have been widely used in clinical peroperative total parenteral nutrition (70). Therefore, this study prove that Omega3 have nephroprotective effects by its antioxidant capacity against amikacin nephrotoxic effect.

REFERENCES

1. Chmielewski, C. Renal anatomy and overview of nephron function. *Nephrol. Nurs. J.* 2003; 30: 185-191.
2. Ganong w F. Review of Medical Physiology. (2 nd edition). McGraw- Hill Medical, 2005; p 699.
3. Alison E. M. Vickers, et al: Kidney Slices of Human and Rat to Characterize Cisplatin-Induced Injury on Cellular Pathways and Morphology. *Toxicologic Pathology*, 2004; 32:577-590.
4. Mary E. Davis and William O. Berdt: Renal Methods for Toxicology. In: principles and Methods for Toxicology (4 th ed), chapter 25, 2001:1189-1213.
5. B. I. Ognjanovic, et al: Effect of chronic cadmium exposure on antioxidant defense system in some tissues of rats: Protective effect of selenium. *Physiol. Res.* 2008; 57: 403-411.
6. Kohli HS., Bhaskaran MC., Muthukumar T., et al: Treatment-related acute renal failure in the elderly: a hospital-based prospective study. *Nephrol Dial Transplant.* 2000; 15 (2):212-217.
7. Mary J. Mycek, Richard A. Harvey and Pamela C. Champe: Aminoglycoside mode of action. In: Lippincott's pharmacology, chapter 31 (2 nd edition), 2002: 311-322.
8. Junya Nagai and Mikihsa Takano: Molecular aspect of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. *Drud Metab. Pharmacokin*, 2004; 19(3); 159-170.
9. Vanessa Barboza de Sousa, et al: Amikacin Induces Renal Morphohistological Alterations in Wistar Rats. *Arquivos de medicina*, 2009; 23(6):205-8.
10. Enver Yazar, Muammer Elmas, Vahdettin, et al: Effects of aminoglycoside antibiotics on renal antioxidants, Malondialdehyde levels, and some serum biochemical parameters. *Candian Journal of veterinary*, 2003; 67: 239-240.
11. Jerry BH and William RH: toxic response of the kidney. In: Casarett and Doull's Toxicology (3rd ed), Curtis D. Klasser (Ed), McGraw-Hill, NewYork, 2001: pp 310-329.
12. Kaloyanides GJ., Bosmans J-L., and De Broe ME.: Antibiotic and Immunosuppression -related renal failure. Schrier RW. Philadelphia PA, 2001.
13. Wojciech Lesniak, Vincent L. Pecoraro, and Jochen Schacht: Ternary Complexes of Gentamicin with Iron and Lipid Catalyze Formation of Reactive Oxygen Species, *Chem. Res. Toxicol.*, 2005, 18 (2), pp 357-364.

14. Carlos Martínez-Salgado a, et al: Glomerular nephrotoxicity of aminoglycosides. *Toxicology and Applied Pharmacology*, 2007; 223: 86–98.
15. Walker, P. D., and S. V. Shah.: Gentamicin enhanced production of hydrogen peroxide by renal cortical mitochondria, *Am J. physiol.*, 1987; 253:495-499.
16. Iekun Ichikawa, Shigeru Kiyama, and Toshimasa Yoshioka: Renal antioxidant enzymes: Their regulation and function. *Kidney International*, 1994; 45: 1-9.
17. Marie-Paule Mingeot-Leclercq and Paul M. Tulkens: Aminoglycosides: Nephrotoxicity. *Antimicrobial Agents and Chemotherapy*, 1999; 43: 1003–1012.
18. JS Sandhu, A Sehgal, O Gupta, A Singh: Aminoglycoside Nephrotoxicity Revisited, *Jiacm*, 2007; 8(4): 331-3.
19. Houghton DC., Plamp CE., Gibert DN., Kohlhepp SJ., Bennett WM., Porter GA., DelFehr J. and Webb M.; Amikacin nephrotoxicity in the rats. *Environ Pathol Toxicol.* 1980 Nov; 4(5-6):277-91.
20. Klein J., Koren G., McLeod SM.: Comparison methods for prediction of nephrotoxicity during development. *Dev Phar-macol Ther* 1992; 19:80– 89
21. Begg EJ. and Barclay ML.: Aminoglycosides 50 years on. *Br J Clin Pharmacol* 1995; 39:597–603.
22. United States Pharmacopeia: USP, 34th ed., United States Pharmacopeial Convention, Rockville, MD, USA, 2011.
23. Prajapati B. and Singha M.: Comparative evaluation of the toxicity of amikacin and cefepime on rat's kidney and liver, *International Journal Pharm Tech Research*, 2010 vol 3(4), pp. 2149-2149-2154, 2010
24. Carlos Martinez- Salgado., et al: Glomerular nephrotoxicity of aminoglycosides. *Toxicology and Applied Pharmacology*, 2007; 223:86- 98.
25. Kaynar K., Gul S., Ersoz S., Ozdemir F. and Ulusoy S.: Amikacin – induced nephrotoxicity: Is there any protective way? *Ren Fail.* 2007; 29(1) 23-7
26. Sharon P. Andreoli: Reactive oxygen molecules, oxidant injury and renal disease, *pediater Nephrol*, 1991; 5: 733-742.
27. Prasad Devarajan: Update on mechanism of ischemic acute kidney injury. *J Am Soc Nephrol*, 2006; 17:1503-1520.
28. Martin, Cathi J; Goeddeke-Merickel, Catherine M. Oxidative stress in chronic kidney disease, *Nephrology Nursing Journal*, 2005;7:1-9.
29. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD: Polyunsaturated fatty acids in the food chain in the United States. *Am J Clin Nutr* 71[Suppl]: 179S–188S, 2000
30. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P: The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. *Arterioscler Thromb* 14: 1829 –1836, 1994 25. Dwyer JH, Allayee H,
31. Dwyer KM, Fan J, Wu H, Mar R, Lusi AJ, Mehrabian M: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. *N Engl J Med* 350: 29 –37, 2004
32. Hughes DA, Pinder AC, Piper Z, Johnson IT, Lund EK: Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. *Am J Clin Nutr* 63: 267–272, 1996
33. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ: The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. *Am J Clin Nutr* 63: 116 –122, 1996 27.
34. Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J 3rd, Spur BW, Robinson DR, Corey EJ, Lewis RA, Austen KF: Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. *N Engl J Med* 312: 1217–1224, 1985 28.
35. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC, et al.: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med* 320: 265–271, 1989
36. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN: Stereochemical assignment, antiinflammatory properties, and receptor for the 190 Clinical Journal of the American Society of Nephrology *Clin J Am Soc Nephrol* 1: 182–192, 2006 omega-3 lipid mediator resolvin E1. *J Exp Med* 201: 713– 722, 2005
37. Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L: Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. *Ann Intern Med* 106: 497–503, 1987
38. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med* 334: 1557– 1560, 1996 32.
39. Ziboh VA, Miller CC, Cho Y: Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: Generation of antiinflammatory and antiproliferative metabolites. *Am J Clin Nutr* 71[Suppl]: 361S–366S, 2000 33.
40. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE: A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. *N Engl J Med* 331: 1194 –1199, 1994
41. Alaa K. J. Al-Rikabi , Nada N Alshawi: Impacts of simultaneous administration of omega-3 fatty acids with amoxicillin/clavulanic acid on albino rats' liver and bile. *Int. J. Pharm. Sci. Rev. Res.*, 41(2), November - December 2016; Article No. 01, Pages: 1-5 ISSN 0976 – 044X
42. Heinegard, D. and Tederstrom, G.: Determination of serum creatinine by direct colorimetric method. *Clin. Chem. Acta.* 1973; 43:305-309.
43. Fawcett, JK and Scott, JE.: Determination of urea in blood or serum. *J Clin. Path.* 1960; 13: 156-159.
44. Walf Droq: Free radical in the physiological control of cell function. *Physiological Review J*, 2002; 82: 47-95.
45. Hadeel Rashid Faraj, Raid M. H. Al-Salih and Adnan T. Al-Khafaji : Study of the Correlation between high sensitivity C reactive protein and Each of Malondialdehyde , Lipid profile, and Atherogenic Index in Patients with Ischemic Heart Diseases(IHD) in Thi-Qar Governorate. *Journal of Education for Pure Science* (2012);4: 2 : 38-51.
46. Fong, K.L., McCay, P.B., and Poyer, J.L., *J. Biol. Chem.* 248:7792; 1973.

47. Schnackenberg G.: "Oxygen radicals in cardiovascular renal disease". *Curr. Opin. Pharmacol*, (2002) 2(2): 121-125.
48. Parlakpınar H., Ozer MK., Sahna E., Vardi N., Cigremis Y. and Acet A.: "Amikacin-induced acute renal injury in rats: protective role of melatonin". *J. Pin. Res.*, (2003) 35(2): 85-90.
49. Hakan P., Ozer M K., Engin S., Nigar V., Yılmaz C. and Ahmet A.: Amikacin-induced acute renal injury in rats: protective role of melatonin. *Journal of Pineal Research*, 2003; 35: 85-90
50. Lopez-Novoa JM., Quiros Y., Vicente L., Morales AI. and Lopez -Hernandez FJ: New insights into the mechanism of aminoglycoside Nephrotoxicity: an integrative point of view. *Kidney Int.* 2011; 79: 33-45.
51. Abd Abdulkareem H., Mohammed Naseer M., Qasim Ban J.: The nephroprotective effects of vardenafil against amikacin induced nephrotoxicity in rabbit. *International Journal of Advanced Research* (2014)
52. Baylis C., Renke HR. and Brenner BM.: Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration. *KidneyInt.*1977; 12:344-53., Issue11, 747-755.ISSN 2320-5407.
53. Atef M. Al-Attar and Wafaa A. Al-Taisan: Preventive effects of black seed (*Nigella Sativa*) extract on Sprague dawley rats exposed to diazinon. *Australian Journal of Basic and applied Sciences*, 2010; 4(5): 957-968.
54. Bulent U., Funda K., and Serap B.: Unable to protect gentamicin -induced nephrotoxicity with allopurinol in rats. *Ankara Univ Vet Fak*, 2006; 53: 65-68
55. Bert W. and Dev. PA.: An expanding view of aminoglycoside-nucleic acid recognition. *Elsevier Inc.* 2006; 16(4):1-5.
56. Abd Abdulkareem H., Mohammed Naseer M., Qasim Ban J.: The nephroprotective effects of vardenafil against amikacin induced nephrotoxicity in rabbit. *International Journal of Advanced Research* (2014), Issue11, 747-755.ISSN 2320-5407.
57. M. Jurczuk, J. Moniuszko-Jakoniuk, J. Rogalska, Glutathione-Related Enzyme Activity in Liver and Kidney of Rats Exposed to Cadmium and Ethanol, *Polish J. of Environ. Stud.*2006; 15:861-868.
58. Hadeel Rashid Faraj, Adnan Taan and Raid Maallak Hannon. Clinical Study for Serum Lipid Profile and Lipid Peroxidation in Patients with Gallstones in Thi-Qar Governorate - Iraq. *ThiQar Medical Journal (TQMJ)*: Vol. (16), No. (2), 2018:(193-199).
59. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. *Clin Chem.*; 41:1819-28, 1995.
60. Gora Dadheech, Sandhya Mishra, Shiv Gautam and Praveen Sharma: Oxidative stress, α -tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. *Indian Journal of Clinical Biochemistry*, 2006; 21 (2) 34-38.
61. Palomero J, Galan AL, Munoz ME, et al: Effects of aging on the susceptibility to the toxic effects of cyclosporine A in rats. Change in liver glutathione and antioxidant enzymes. *J free radic boil med.*, 2002; 30: 836-845.
62. Ihab T Abdwl-Raheem, Gamal A EI-Sherbiny and Ashraf Taye: Green tea ameliorates renal oxidative damage induced by gentamicin in rats. *Pak. J. Pharm*, 2010; 23: 21-28.
63. Williams PH., Lopez DB., Chan C., Ezrin A. and Hotten-Dorf R.: Characterization of renal ischemia-reperfusion injury in rats. *J Pharmacol Toxicol Meth* 1997; 37: 1-7.
64. Sahnae, Parlakpınarh, Cihan Of., Turkozy and Aceta. : Effects of aminoguanidine against renal ischaemia-reperfusion injury in rats. *Cell Biochem Funct* 2006; 24: 137-141.
65. Nagai J., Tanaka H., Nakanishi N., Murakami T. and Takano M.: Role of megalin in renal handling of aminoglycosides. *Am J Physiol Renal Physiol* 2001;28: 337-344.
66. Lara T. Meital et al: Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages from patients with small abdominal aortic aneurysm, Article number: 12978 (2019) nature research
67. G. Calviello and S. Serini, *Dietary Omega-3 Polyunsaturated Fatty Acids and Cancer*, Springer, London, UK, 2010.
68. A. A. Shaikh, I. Brown, K. W. J. Wahle, and S. D. Heys, "Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids," *Nutrition and Cancer*, vol. 62, no. 3, pp. 284-296, 2010.
69. P. C. Calder, "Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale," *Biochimie*, vol. 91, no. 6, pp. 791-795, 2009.
70. B. Koletzko and O. Goulet, "Fish oil containing intravenous lipid emulsions in parenteral nutrition-associated cholestatic liver disease," *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 13, no. 3, pp. 321-326, 2010